Dana-Farber Cancer Institute

Belkins
"The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to our target community across the United States and throughout the world. The Jimmy Fund is the principal charity of the Institute. The Boston Red Sox adopted the Jimmy Fund as its official charity in 1953 and continues to prominently sponsor the charity."

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DANA-FARBER CANCER INSTITUTE, LIFESPAN PARTNERSHIP MOVES FORWARD WITH AGREEMENT SIGNING

Dana-Farber Cancer Institute | September 22, 2016

news image

Dana-Farber Cancer Institute and Lifespan leadership have signed a memorandum of understanding to form a partnership that will advance cancer treatment and expand research. The details will be finalized early next year....

Read More

DISCOVERY OFFERS PROSPECT OF SHORTER TREATMENT AND CURE FOR CHRONIC MYELOGENOUS LEUKEMIA

Dana-Farber Cancer Institute | September 14, 2016

news image

Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. In new research that could suggest a road to cure, scientists at Dana-Farber Cancer Institute and Boston Children’s Hospital have found that CML stem cells die in response to inhibition of a protein called Ezh2....

Read More

WILLIAM G. KAELIN JR., MD, DANA-FARBER RESEARCHER, AWARDED 2016 LASKER AWARD FOR BASIC MEDICAL RESEARCH

Dana-Farber Cancer Institute | September 13, 2016

news image

William G. Kaelin Jr., MD, professor in the Department of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, has been named a winner of the 2016 Lasker Award for Basic Medical Research by the Albert and Mary Lasker Foundation. Kaelin, along with Peter J. Ratcliffe (University of Oxford/Francis Crick Institute), and Gregg L. Semenza (Johns Hopkins University School of Medicine) were cited for the discovery of the pathway by which cells from humans and most animals sense and adap...

Read More

ANTIBODY DISCOVERY COULD HELP CREATE IMPROVED FLU VACCINES

Dana-Farber Cancer Institute | September 13, 2016

news image

Dana-Farber Cancer Institute investigators report they have discovered a type of immune antibody that can rapidly evolve to neutralize a wide array of influenza virus strains – including those the body hasn’t yet encountered....

Read More
news image

DANA-FARBER CANCER INSTITUTE, LIFESPAN PARTNERSHIP MOVES FORWARD WITH AGREEMENT SIGNING

Dana-Farber Cancer Institute | September 22, 2016

Dana-Farber Cancer Institute and Lifespan leadership have signed a memorandum of understanding to form a partnership that will advance cancer treatment and expand research. The details will be finalized early next year....

Read More
news image

DISCOVERY OFFERS PROSPECT OF SHORTER TREATMENT AND CURE FOR CHRONIC MYELOGENOUS LEUKEMIA

Dana-Farber Cancer Institute | September 14, 2016

Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. In new research that could suggest a road to cure, scientists at Dana-Farber Cancer Institute and Boston Children’s Hospital have found that CML stem cells die in response to inhibition of a protein called Ezh2....

Read More
news image

WILLIAM G. KAELIN JR., MD, DANA-FARBER RESEARCHER, AWARDED 2016 LASKER AWARD FOR BASIC MEDICAL RESEARCH

Dana-Farber Cancer Institute | September 13, 2016

William G. Kaelin Jr., MD, professor in the Department of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, has been named a winner of the 2016 Lasker Award for Basic Medical Research by the Albert and Mary Lasker Foundation. Kaelin, along with Peter J. Ratcliffe (University of Oxford/Francis Crick Institute), and Gregg L. Semenza (Johns Hopkins University School of Medicine) were cited for the discovery of the pathway by which cells from humans and most animals sense and adap...

Read More
news image

ANTIBODY DISCOVERY COULD HELP CREATE IMPROVED FLU VACCINES

Dana-Farber Cancer Institute | September 13, 2016

Dana-Farber Cancer Institute investigators report they have discovered a type of immune antibody that can rapidly evolve to neutralize a wide array of influenza virus strains – including those the body hasn’t yet encountered....

Read More